An Individualized Prognostic Model in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Based on Serum Metabolomic Profiling
Life · 11.05.2023 · 13 (5) · 1167
DOI: 10.3390/life13051167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life, online erschienen am 11.05.2023. Verfasst von Jiayu Zhou und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University C…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Basic and Applied Basic Research Foundation of Guangdong Province, the National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Purpose
This study aims to evaluate the value of a serum metabolomics-based metabolic signature for locoregionally advanced nasopharyngeal carcinoma (LA-NPC) patients, thereby assisting clinical decisions.
Methods
In this retrospective study, a total of 320 LA-NPC patients were randomly divided into a training set (ca. 70%; n = 224) and a validation set (ca. 30%; n = 96). Serum samples were analyzed using widely targeted metabolomics. Univariate and multivariate Cox regression analyses were used to identify candidate metabolites related to progression-free survival (PFS). Patients were categorized into high-risk and low-risk groups based on the median metabolic risk score (Met score), and the PFS difference between the two groups was compared using Kaplan–Meier curves. The predictive performance of the metabolic signature was evaluated using the concordance index (C-index) and the time-dependent receiver operating characteristic (ROC), and a comprehensive nomogram was constructed using the Met score and other clinical factors.
Results
Nine metabolites were screened to build the metabolic signature and generate the Met score, which effectively separated patients into low- and high-risk groups. The C-index in the training and validation sets was 0.71 and 0.73, respectively. The 5-year PFS was 53.7% (95% CI, 45.12–63.86) in the high-risk group and 83.0% (95%CI, 76.31–90.26) in the low-risk group. During the construction of the nomogram, Met score, clinical stage, pre-treatment EBV DNA level, and gender were identified as independent prognostic factors for PFS. The predictive performance of the comprehensive model was better than that of the traditional model.
Conclusion
The metabolic signature developed through serum metabolomics is a reliable prognostic indicator of PFS in LA-NPC patients and has important clinical significance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
- Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
- Department of Information, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
- School of Electronics and Information Technology (School of Microelectronics), Sun Yat-sen University, Guangzhou 510275, China.
- The First School of Clinical Medicine, Southern Medical University, No. 1023, South Shatai Road, Baiyun District, Guangzhou 510515, China.
- Department of Critical Care Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
ORCID-Profile: Yishu Deng
Förderung
- the Basic and Applied Basic Research Foundation of Guangdong Province
- the National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
Zitieren
APA
Zhou, J., Deng, Y., Huang, Y., Wang, Z., Zhan, Z., Cao, X., Cai, Z., Deng, Y., Zhang, L., Huang, H., Li, C., & Lv, X. (2023). An Individualized Prognostic Model in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Based on Serum Metabolomic Profiling. Life, 13(5), 1167. https://doi.org/10.3390/life13051167
Vancouver
Zhou J, Deng Y, Huang Y, Wang Z, Zhan Z, Cao X, et al. An Individualized Prognostic Model in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Based on Serum Metabolomic Profiling. Life. 2023;13(5):1167. doi:10.3390/life13051167
BibTeX
@article{Zhou2023,
author = {Zhou, Jiayu and Deng, Yishu and Huang, Yingying and Wang, Zhiyi and Zhan, Zejiang and Cao, Xun and Cai, Zhuochen and Deng, Ying and Zhang, Lulu and Huang, Haoyang and Li, Chaofeng and Lv, Xing},
title = {An Individualized Prognostic Model in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Based on Serum Metabolomic Profiling},
journal = {Life},
year = {2023},
volume = {13},
number = {5},
pages = {1167},
doi = {10.3390/life13051167}
}
EUVIMED